Mathematical Biosciences and Engineering, 2015, 12(6): 1219-1235. doi: 10.3934/mbe.2015.12.1219.

Primary: 92C37, 92C50; Secondary: 92C45.

Export file:

Format

  • RIS(for EndNote,Reference Manager,ProCite)
  • BibTex
  • Text

Content

  • Citation Only
  • Citation and Abstract

An integrated cellular and sub-cellular model of cancer chemotherapy and therapies that target cell survival

1. Department of Applied Mathematics, Brown University, 182 George Street, Providence, RI 02906
2. Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109
3. Department of Mathematics, University of Michigan, 530 Church Street, Ann Arbor, MI 48109-1043

Apoptosis resistance is a hallmark of human cancer, and tumor cells often become resistant due to defects in the programmed cell death machinery.Targeting key apoptosis regulators to overcome apoptotic resistance and promote rapid death of tumor cells is an exciting new strategy for cancer treatment, either alone or in combination with traditionally used anti-cancer drugs that target cell division. Here we present a multiscale modeling framework for investigating the synergism between traditional chemotherapy and targeted therapies aimed at critical regulators of apoptosis.
  Figure/Table
  Supplementary
  Article Metrics

Keywords cisplatin.; Multiscale model; cancer therapy

Citation: Alexis B. Cook, Daniel R. Ziazadeh, Jianfeng Lu, Trachette L. Jackson. An integrated cellular and sub-cellular model of cancer chemotherapy and therapies that target cell survival. Mathematical Biosciences and Engineering, 2015, 12(6): 1219-1235. doi: 10.3934/mbe.2015.12.1219

References

  • 1. Science, 281 (1998), 1322-1326.
  • 2. PLoS One, 9 (2014), e99404.
  • 3. Nature, 415 (2002), 922-926.
  • 4. Oncogene, 27 (2009), S128-S136.
  • 5. Annu. Rev. Immunol., 16 (1998), 395-419.
  • 6. J. Biol. Chem., 269 (1994), 787-790.
  • 7. Neoplasia, 5 (2003), 161-169.
  • 8. Cancers, 3 (2011), 1351-1371.
  • 9. Ann NY Acad Sci, 1010 (2003), 153-158.
  • 10. Mol. Pharmacol., 59 (2001), 657-663.
  • 11. PLoS One, 9 (2014), e81582.
  • 12. Cancer Res., 71 (2011), 705-715.
  • 13. Mol. Cancer There., 8 (2009), 2926-2936.
  • 14. Bull. Math. Biol., 70 (2008), 89-117.
  • 15. J Neurochem, 84 (2003), 273-281.
  • 16. Chem. Rev., 107 (2007), 1387-1407.
  • 17. J. Biol. Chem., 286 (2011), 14564-14574.
  • 18. Clin. Cancer Res., 9 (2003), 4287-4295.
  • 19. J. Exp Clin. Cancer Res., 31 (2012), p102.
  • 20. Mol. Cell., 6 (2000), 1389-1399.
  • 21. Mol. Cancer Ther., 8 (2009), 10-16.
  • 22. Cancers, 3 (2011), 415-427.
  • 23. Adv Studies in Biol, 4 (2012), 19-25.
  • 24. Int. J. Oncol., 29 (2006), 471-479.
  • 25. Nature, 407 (2000), 810-816.
  • 26. Cancer Res., 73 (2013), 5485-5496.
  • 27. Oncologist, 15 (2010), 994-1001.
  • 28. Nat. Rev. Drug Discov., 1 (2002), 111-121.
  • 29. Adv. in Pharm., 41 (1997), 501-532.
  • 30. J. Clin. Oncol., 30 (2012), 488-496.
  • 31. Clin. Cancer Res., 1 (1995), 981-989.
  • 32. JNCI., 82 (1990), 749-755.
  • 33. Adv. Cancer Res., 108 (2010), 73-112.
  • 34. Hemotol., 1 (2005), 226-230.
  • 35. Ind. Eng. Chem. Res., 50 (2011), 12872-12880.
  • 36. Chem. Res. Toxicol., 17 (2004), 1434-1444.
  • 37. Eur. J. Cancer, 28 (1992), 82-86.
  • 38. Cancer Res., 68 (2008), 3421-3428.
  • 39. Scient, 292 (2001), 727-730.

 

This article has been cited by

  • 1. Fuli Wang, Rongxiang Zhang, Yong Cui, Liping Sheng, Yinping Sun, Wei Tian, Xiao Liu, Shuzeng Liang, Design, synthesis and biological evaluation of 3,4-dihydronaphthalen-1(2H)-one derivatives as Bcl-2 inhibitors, Research on Chemical Intermediates, 2017, 43, 10, 5933, 10.1007/s11164-017-2972-x
  • 2. Ning Li, Wen-Yu Xin, Bin-Rong Yao, Chun-Hua Wang, Wei Cong, Feng Zhao, Hong-Juan Li, Yun Hou, Qing-Guo Meng, Gui-Ge Hou, Novel dissymmetric 3,5-bis(arylidene)-4-piperidones as potential antitumor agents with biological evaluation in vitro and in vivo, European Journal of Medicinal Chemistry, 2018, 147, 21, 10.1016/j.ejmech.2018.01.088
  • 3. Ning Li, Binrong Yao, Chunhua Wang, Qingguo Meng, Guige Hou, Synthesis, crystal structure and activity evaluation of novel 3,4-dihydro-1-benzoxepin-5(2H)-one derivatives as protein–tyrosine kinase (PTK) inhibitors, Acta Crystallographica Section C Structural Chemistry, 2017, 73, 11, 1003, 10.1107/S2053229617015145
  • 4. Binrong Yao, Ning Li, Chunhua Wang, Guige Hou, Qingguo Meng, Ke Yan, Novel asymmetric 3,5-bis(arylidene)piperidin-4-one derivatives: synthesis, crystal structures and cytotoxicity, Acta Crystallographica Section C Structural Chemistry, 2018, 74, 6, 659, 10.1107/S2053229618006605

Reader Comments

your name: *   your email: *  

Copyright Info: 2015, Alexis B. Cook, et al., licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution Licese (http://creativecommons.org/licenses/by/4.0)

Download full text in PDF

Export Citation

Copyright © AIMS Press All Rights Reserved